Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Canopy Growth (CGC – Research Report).
Regeneron (REGN)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Regeneron, with a price target of $980.00. The company’s shares closed last Wednesday at $874.37, close to its 52-week high of $887.94.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $937.50 average price target, a 10.6% upside from current levels. In a report issued on December 12, Morgan Stanley also maintained a Buy rating on the stock with a $941.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Canopy Growth (CGC)
In a report released yesterday, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Canopy Growth, with a price target of $5.30. The company’s shares closed last Wednesday at $5.21, close to its 52-week low of $3.46.
Lewandowski has an average return of
According to TipRanks.com, Lewandowski is ranked #1189 out of 8665 analysts.
Currently, the analyst consensus on Canopy Growth is a Moderate Sell with an average price target of $1.47.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Regeneron (NASDAQ:REGN) Gains after Patent Suit Mostly Wins
- Regeneron VP Fenimore sells $1.6M in company shares
- Regeneron price target raised to $1,125 from $1,050 at Oppenheimer
- Regeneron’s treatment of Hemophilia B granted FDA orphan designation
- Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
